Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C. Garcia-Echeverria
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
Cancer Research
Cancer Research
Oncology
Related publications
The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
Frontiers in Oncology
Cancer Research
Oncology
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Clinical Cancer Research
Cancer Research
Oncology
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer
International Journal of Oncology
Cancer Research
Oncology
Shiga Toxin 1-Induced Proinflammatory Cytokine Production Is Regulated by the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
Infection and Immunity
Parasitology
Infectious Diseases
Immunology
Microbiology
NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro
Acta Pharmacologica Sinica
Medicine
Pharmacology
Interferon Α-Induced Apoptosis in Tumor Cells Is Mediated Through the Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Signaling Pathway
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Phosphoinositide-3 Kinase/Protein Kinase-B/Mammalian Target of Rapamycin Pathway in Psoriasis Pathogenesis. A Potential Therapeutic Target?
Acta Dermato-Venereologica
Dermatology
Medicine
Ku-0063794 Is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)
Biochemical Journal
Biochemistry
Cell Biology
Molecular Biology
